Targeting of the BCR pathway in patients resistant to ibrutinib. Schematic of the BCR pathway highlighting kinases currently targetable with small-molecule inhibitors. These targets may be of interest in patients who relapse after ibrutinib therapy. BLNK indicates B-cell linker; DAG, diacylglycerol; IP3, inositol triphosphate; NFAT, nuclear factor of activated T-cell; PIP2, phosphatidylinositol-4,5-biphosphate; PIP3, phosphatidylinositol-3,4,5-triphosphate.